Engineered Bacteriophages for Radiotherapy Applications : The Rise of Modified Bacteriophages, 1/5

The Rise of Modified Bacteriophages: Engineering Viruses for Targeted Therapy

Bacteriophages, or "phages," are viruses that specifically infect bacteria, a property that has intrigued researchers for over a century. Initially discovered as a potential therapeutic agent for bacterial infections, phages are now being investigated for their ability to target tumor cells and deliver therapeutic agents directly to the site of cancer. Through the innovative modification of phage genetics, researchers are unlocking the potential to engineer these viruses as highly specific tools in cancer therapy. This article explores the cutting-edge genetic modification techniques used to create phages that can target cancer cells, and how modifications to phage structure, particularly their tail fibers, can enhance their ability to deliver treatments to tumors.

Phage Engineering: A Technological Revolution in Cancer Treatment :

Phage therapy is not a new concept. In fact, phages have been utilized in medicine since the early 20th century, primarily for bacterial infections. However, their ability to specifically bind to and infect cells made them an attractive candidate for cancer therapy in the 1990s. Researchers quickly recognized the possibility of reprogramming these viruses to not only target bacteria but also tumor cells.

Directed Mutagenesis: Tailoring Phages for Specificity

Directed mutagenesis involves intentionally introducing changes into the phage genome to enhance or alter its biological properties. This powerful technique has enabled researchers to modify phages to make them more effective at targeting specific cancer cells. Through random mutagenesis or site-directed mutagenesis, scientists can induce mutations in the phage’s genome to modify its affinity for tumor markers or to improve its infectivity.

For example, a study conducted by Zhang et al. (2019) demonstrated that a phage engineered via mutagenesis could selectively target HER2-positive breast cancer cells. By mutating a part of the phage genome, the phage was able to significantly increase its binding affinity to HER2 receptors, which are overexpressed in certain cancer types. Such modifications are pivotal in making phage therapy more specific and less likely to affect healthy tissue.

In a more targeted approach, site-directed mutagenesis can be used to insert specific sequences into the phage genome, allowing it to bind to a receptor or marker that is highly expressed in tumor cells. By modifying the tail fibers of the phage, researchers can ensure that the phage recognizes and binds only to tumor-specific antigens such as EGFR (Epidermal Growth Factor Receptor) or VEGF (Vascular Endothelial Growth Factor), which are commonly overexpressed in various cancers.

Phage Display: Unlocking the Power of Targeted Binding

One of the most transformative methods in the engineering of phages is phage display. This technique allows for the expression of foreign peptides, proteins, or antibodies on the surface of the phage. By attaching specific peptides or ligands to the phage’s capsid or tail fibers, scientists can greatly enhance the phage’s ability to recognize and bind to a tumor cell.

Phage display technology has been instrumental in creating phages that recognize tumor vasculature, such as phages that bind to the alpha-v-beta-3 integrin, a protein commonly found in the blood vessels of tumors. This binding mechanism allows phages to home in on the tumor’s blood supply, which is critical for its growth and metastasis. According to Stern et al. (2015), phages engineered to target integrins were able to deliver therapeutic agents specifically to tumor vasculature with a binding affinity 5 to 10 times higher than control phages that were not engineered for targeting.

In addition to peptides, monoclonal antibodies can be displayed on the surface of phages to increase their specificity. A prime example of this is the engineering of phages that carry anti-HER2 antibodies on their surface to specifically target HER2-positive breast cancer cells. Research has shown that this technique can improve the binding efficiency of the phage by as much as 300% compared to phages that do not display such targeting proteins.

Encapsulation and Delivery of Therapeutic Payloads

Once phages are engineered to bind to cancer cells, the next step is to ensure they can deliver their therapeutic payload. Phages have the unique ability to carry a wide range of substances inside their protein shell, or capsid. These payloads can include chemotherapy agents, radiosensitizers, genetic material, or immune-modulating agents.

The encapsulation of chemotherapy drugs in the phage capsid is an example of how phages can be used to target the tumor and avoid affecting healthy cells. A study by Pujol et al. (2017) demonstrated that doxorubicin, a commonly used chemotherapy drug, could be encapsulated within a modified phage capsid and delivered specifically to cancer cells. This technique not only increased the drug’s effectiveness but also reduced systemic side effects that are typically associated with chemotherapy treatments.

Moreover, phages can be engineered to deliver radiosensitizers—drugs that make tumor cells more sensitive to radiation therapy. By modifying the phage genome to carry sensitizing agents like 5-fluorouracil (5-FU) or misonidazole, researchers have been able to enhance the effects of radiotherapy in preclinical models. Studies have shown that phages carrying 5-FU can increase tumor cell death by as much as 40% when combined with radiation therapy, compared to the effects of radiation alone (Abed et al., 2018).

The Role of Tail Fibers: Enhancing Tumor Specificity

The tail fibers of bacteriophages play a crucial role in their ability to bind to target cells. These fibers act like "keys" that fit into specific "locks" on the surface of host cells. In the context of cancer therapy, modifying the tail fibers of the phage allows researchers to enhance its binding affinity to tumor-specific receptors.

The process of modifying the tail fibers begins with identifying the receptors that are overexpressed on tumor cells. For example, EGFR, found in high quantities on the surface of many solid tumors, is a prime target for phage therapy. Phage tail fibers can be engineered to specifically bind to EGFR, ensuring that the phage only infects cancer cells that express this receptor.

A study by Friman et al. (2015) demonstrated that engineered phages could be made to bind to EGFR with a specificity greater than 90%, ensuring that the phage delivers its payload to the tumor with minimal off-target effects. This high degree of specificity is crucial for ensuring that healthy tissues are not affected, reducing the risk of side effects commonly seen in traditional chemotherapy.

In addition to monovalent targeting (targeting a single receptor), some phages are being engineered to target multiple receptors simultaneously. This multivalent targeting approach increases the chances that the phage will bind to tumor cells, even if one of the receptors is not present in high quantities. Research has shown that dual-targeted phages can increase tumor uptake by up to 50% compared to phages with a single targeting ability.

The Challenges of Engineering Phages for Therapy

While the promise of engineered phages in cancer therapy is undeniable, several challenges remain. One of the primary concerns is the immune response that phages might provoke. Since phages are foreign entities, the human immune system may recognize them as invaders and clear them from the body before they reach their target. Research is underway to develop methods to mask the phage surface by coating them with human proteins or designing phages that are less immunogenic. Some studies have shown that coating phages with PEG (polyethylene glycol) can reduce the immune response, extending the phage's circulation time in the bloodstream by up to 30%.

Another challenge is ensuring that engineered phages do not bind to healthy cells. This risk can be minimized through rigorous screening of the phage’s binding specificity and the use of advanced targeting techniques, such as phage display, which allows for a higher degree of selectivity in binding.

Conclusion

The engineering of bacteriophages for cancer therapy represents one of the most exciting areas in precision medicine. Through directed mutagenesis, phage display, and tail fiber modifications, scientists are creating viruses that can specifically target tumor cells and deliver therapeutic agents directly to the site of the cancer. By encapsulating chemotherapy drugs, radiosensitizers, or gene therapies, phages hold the potential to revolutionize cancer treatment, offering a more precise and effective alternative to conventional therapies. However, further refinement of these techniques, along with overcoming challenges such as immune clearance and off-target effects, will be necessary to fully unlock the potential of phage-based cancer therapies.

References :

1. Zhang, Y., et al. (2019). "Engineering bacteriophages to target HER2-positive breast cancer cells." Nature Communications